Publicacions en col·laboració amb investigadors/es de University College London (19)

2024

  1. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx (Nature, (2023), 616, 7957, (525-533), 10.1038/s41586-023-05783-5)

    Nature

  2. Fcγ receptors and immunomodulatory antibodies in cancer

    Nature Reviews Cancer, Vol. 24, Núm. 1, pp. 51-71

  3. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

    Nature Communications, Vol. 15, Núm. 1

  4. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models

    Nature Communications , Vol. 15, Núm. 1

  5. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

    Nature Cancer, Vol. 5, Núm. 2, pp. 347-363

2023

  1. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

    Nature, Vol. 616, Núm. 7957, pp. 563-573

  2. Body composition and lung cancer-associated cachexia in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 846-858

  3. Genomic–transcriptomic evolution in lung cancer and metastasis

    Nature, Vol. 616, Núm. 7957, pp. 543-552

  4. Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials

    The oncologist, Vol. 28, Núm. 4, pp. e205-e211

  5. Lung adenocarcinoma promotion by air pollutants

    Nature, Vol. 616, Núm. 7955, pp. 159-167

  6. The evolution of lung cancer and impact of subclonal selection in TRACERx

    Nature, Vol. 616, Núm. 7957, pp. 525-533

  7. The evolution of non-small cell lung cancer metastases in TRACERx

    Nature, Vol. 616, Núm. 7957, pp. 534-542

  8. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

    Nature, Vol. 616, Núm. 7957, pp. 553-562

2022

  1. A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer

    Nature Cancer, Vol. 3, Núm. 6, pp. 696-709

  2. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling

    Nature Cancer, Vol. 3, Núm. 11, pp. 1336-1350

  3. Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1)

    Nature Cancer

2021

  1. Clarification of Definitions of Hyperprogressive Disease during Immunotherapy

    JAMA Oncology

2020

  1. Atypical patterns of response and progression in the era of immunotherapy combinations

    Future Oncology, Vol. 16, Núm. 23, pp. 1707-1713

  2. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors

    Annals of Oncology, Vol. 31, Núm. 10, pp. 1405-1412